New Survey Ranks Diarrhea as Number One Gastrointestinal Complaint of HIV/AIDS Patients
“While it’s typically not the main reason patients come to see me,
frequently my patients with HIV inform me that they suffer from chronic
diarrhea. Worth noting, diarrhea appears to be more common in patients
who have been HIV-positive for several years; this is most likely due to
HIV enteropathy, which is the effect of the virus on the lining of the
intestine,” noted Dr.
Highlights of the survey of U.S. board certified gastroenterologists include:
- 93 percent of U.S. gastroenterologists see patients with HIV/AIDS in their practice
- 84 percent rank diarrhea in the top three complaints of HIV/AIDS patients
- 53 percent indicated diarrhea is the number one complaint in HIV/AIDS patients
- 65 percent of diarrhea in HIV/AIDS patients is chronic
Only 53 percent of gastroenterologists were aware of Mytesi®
(crofelemer), the only drug that has been specifically studied in and
“Chronic diarrhea remains a significant, under-reported complaint of
HIV/AIDS patients, and it is a problem that will increase significantly
as the HIV+ population gets older. According to data from the
To view an infographic of the study results click here: http://enoughdiarrhea.com/infographic/
Launched by Napo in
To learn more about what you can do about HIV/AIDS-related diarrhea, visit www.mytesi.com.
Napo sponsored the survey of 271 U.S. board certified
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the
As previously announced, the merger of
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding possible follow-on indications for Mytesi®. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.